Literature DB >> 10441745

Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1).

D M Pitterle1, Y C Kim, E M Jolicoeur, Y Cao, K C O'Briant, G Bepler.   

Abstract

LOH11A is a region of Chromosome (Chr) 11p15.5 where 75% of lung cancers show loss of heterozygosity (LOH). Clinical and cell biological studies suggest that LOH11A contains a tumor/metastasis suppressor gene. We have mapped this region (650 kb) using overlapping genomic P1/PAC/BAC clones, and one of the genes that we have identified is RRM1. This gene encodes the large subunit (M1) of ribonucleotide reductase, the heterodimeric enzyme that catalyzes the rate-limiting step in deoxyribonucleotide synthesis. By comparing our genomic sequences with the previously published cDNA, we have found that the human gene is composed of 19 exons. It is oriented telomere to centromere and is Alu rich. In order to verify that RRM1 maps within the boundaries of LOH11A, we assessed the frequency of LOH at a SacI polymorphism within intron IX of the gene. We observed LOH in 48% (15/31) of informative lung tumor specimens. To determine whether RRM1 was mutated in tumors, SSCP analysis of the 19 RRM1 exons was performed. No mutations were revealed in 12 pairs of normal and tumor DNA samples. Immunoblots on protein extracts from normal/tumor pairs indicated that a protein of the expected size was present in both. Our conclusion is that RRM1 lies within the LOH11A region, but that its exons are not mutated in tumors. The potential for RRM1 to act as a tumor suppressor is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441745     DOI: 10.1007/s003359901114

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  15 in total

1.  Nuclear RNR-α antagonizes cell proliferation by directly inhibiting ZRANB3.

Authors:  Yuan Fu; Marcus J C Long; Somsinee Wisitpitthaya; Huma Inayat; Timothy M Pierpont; Islam M Elsaid; Jordana C Bloom; Joaquin Ortega; Robert S Weiss; Yimon Aye
Journal:  Nat Chem Biol       Date:  2018-08-27       Impact factor: 15.040

Review 2.  Parameters for individualizing systemic therapy in non-small cell lung cancer.

Authors:  Shirish M Gadgeel; Michele L Cote; Ann G Schwartz; Larry H Matherly; Antoinette Wozniak; Gerold Bepler
Journal:  Drug Resist Updat       Date:  2010-11-03       Impact factor: 18.500

3.  Pharmacogenomics: a reality or still a promise?

Authors:  Gerold Bepler
Journal:  Lung Cancer       Date:  2006-10-24       Impact factor: 5.705

4.  Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.

Authors:  Zhi-Liang Huang; Xun Cao; Ruo-Zhen Luo; You-Fang Chen; Lin-Chun Zhu; Zhesheng Wen
Journal:  Oncol Lett       Date:  2015-11-09       Impact factor: 2.967

Review 5.  Metastasis suppressor genes at the interface between the environment and tumor cell growth.

Authors:  Douglas R Hurst; Danny R Welch
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

6.  Alterations in gene expression and DNA methylation during murine and human lung alveolar septation.

Authors:  Alain Cuna; Brian Halloran; Ona Faye-Petersen; David Kelly; David K Crossman; Xiangqin Cui; Kusum Pandit; Naftali Kaminski; Soumyaroop Bhattacharya; Ausaf Ahmad; Thomas J Mariani; Namasivayam Ambalavanan
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

Review 7.  Metastasis suppressors in breast cancers: mechanistic insights and clinical potential.

Authors:  Christopher R Bohl; Sitaram Harihar; Warren L Denning; Rahul Sharma; Danny R Welch
Journal:  J Mol Med (Berl)       Date:  2013-12-06       Impact factor: 4.599

8.  RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.

Authors:  Chuan Zeng; Weidong Fan; Xianquan Zhang
Journal:  Cell Oncol (Dordr)       Date:  2015-06-20       Impact factor: 6.730

9.  Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.

Authors:  Xue-Feng Leng; Ming-Wu Chen; Lei Xian; Lei Dai; Guang-Yao Ma; Man-Hong Li
Journal:  J Exp Clin Cancer Res       Date:  2012-03-23

10.  The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer.

Authors:  Clorinda Schettino; Maria A Bareschino; Paolo Maione; Antonio Rossi; Fortunato Ciardiello; Cesare Gridelli
Journal:  Curr Genomics       Date:  2008-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.